Case | Age | Myometrial invasion | Heterologous element | Immunophenotype | Lymphnode metastasis/ vascular invasion | Surgical treatment | Adjuvant treatment |
---|---|---|---|---|---|---|---|
Park H.M. et al case [3] | 37 | No | No | Vimentin: ++ CD34: - HMB-45: - Desmin: - Cytokeratin: - S-100: - CD99: - SMA: +/- | No | TAH + BSO+ PLA | No |
ComunoÄŸlu N. et al case [4] | 60 | No | No | Vimentin: ++ CD34: - HMB-45: - Cytokeratin: - S-100: - Pg: + E: + SMA and Desmin: + in sarcomatous stromal cell | No | TAH + BSO | No |
Duggal R. et al case [5] | 15 | No | Yes: chondrosarcoma, myxoid liposarcoma, leiomyosarcoma, rhabdomyosarcoma | Vimentin: + in low grade sarcomatous areas; ++ in high grade sarcomatous areas CD10: + in low grade sarcomatous areas S-100: + in liposarcomatous areas Pg: - E: - | - | TAH + BSO + O + PW | CHT RT |
Present case | 72 | Yes: focal invasion | Yes: rhabdomyosarcoma | Vimentin: ++ keratin (MNF 16): +/- MYF4: +/- B-hCG: - Pg: - E: - SMA: - | No | TAH + BSO+ PLA O + PW + A | CHT RT |